JP2001511463A - 転移予防のための医薬の製造のためのタウロリジンまたはタウルルタムの使用 - Google Patents
転移予防のための医薬の製造のためのタウロリジンまたはタウルルタムの使用Info
- Publication number
- JP2001511463A JP2001511463A JP2000504921A JP2000504921A JP2001511463A JP 2001511463 A JP2001511463 A JP 2001511463A JP 2000504921 A JP2000504921 A JP 2000504921A JP 2000504921 A JP2000504921 A JP 2000504921A JP 2001511463 A JP2001511463 A JP 2001511463A
- Authority
- JP
- Japan
- Prior art keywords
- solution
- taurolidine
- heparin
- taurultam
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AJKIRUJIDFJUKJ-UHFFFAOYSA-N taurolidine Chemical compound C1NS(=O)(=O)CCN1CN1CNS(=O)(=O)CC1 AJKIRUJIDFJUKJ-UHFFFAOYSA-N 0.000 title claims abstract description 54
- 229960004267 taurolidine Drugs 0.000 title claims abstract description 54
- RJGYJMFQWGPBGM-UHFFFAOYSA-N 1,2,4-thiadiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCN1 RJGYJMFQWGPBGM-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 229950007343 taurultam Drugs 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims description 5
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 206010027476 Metastases Diseases 0.000 title description 14
- 230000009401 metastasis Effects 0.000 title description 9
- 230000002265 prevention Effects 0.000 title description 2
- 230000006510 metastatic growth Effects 0.000 claims abstract description 19
- 238000002357 laparoscopic surgery Methods 0.000 claims abstract description 18
- 238000001356 surgical procedure Methods 0.000 claims abstract description 18
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 27
- 229920000669 heparin Polymers 0.000 claims description 24
- 229960002897 heparin Drugs 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 15
- 238000001802 infusion Methods 0.000 claims description 10
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 7
- 229920002674 hyaluronan Polymers 0.000 claims description 7
- 229960003160 hyaluronic acid Drugs 0.000 claims description 7
- 239000000443 aerosol Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000002324 minimally invasive surgery Methods 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 239000002628 heparin derivative Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 13
- 230000003211 malignant effect Effects 0.000 description 12
- 210000001015 abdomen Anatomy 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 230000003187 abdominal effect Effects 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 210000000683 abdominal cavity Anatomy 0.000 description 5
- 238000012084 abdominal surgery Methods 0.000 description 5
- 238000002350 laparotomy Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 210000003815 abdominal wall Anatomy 0.000 description 4
- 210000003200 peritoneal cavity Anatomy 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000005646 Pneumoperitoneum Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000035965 Postoperative Complications Diseases 0.000 description 2
- 239000012891 Ringer solution Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000006678 Abdominal Neoplasms Diseases 0.000 description 1
- 208000007743 Acute Abdomen Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 238000012752 Hepatectomy Methods 0.000 description 1
- 206010019646 Hepatic cyst Diseases 0.000 description 1
- 206010061207 Hernia obstructive Diseases 0.000 description 1
- 208000034991 Hiatal Hernia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010062062 Large intestinal obstruction Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010041101 Small intestinal obstruction Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000007486 appendectomy Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 201000011603 cardia cancer Diseases 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002192 cholecystectomy Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002016 colloidosmotic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000010878 colorectal surgery Methods 0.000 description 1
- 210000001953 common bile duct Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000009799 cystectomy Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000002674 endoscopic surgery Methods 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013110 gastrectomy Methods 0.000 description 1
- 208000029493 gastroesophageal disease Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 238000007453 hemicolectomy Methods 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 201000006823 malignant adenoma Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000010727 rectal prolapse Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9716219.2 | 1997-07-31 | ||
| GBGB9716219.2A GB9716219D0 (en) | 1997-07-31 | 1997-07-31 | Prevention of metastases |
| PCT/GB1998/002311 WO1999006114A2 (en) | 1997-07-31 | 1998-07-31 | Use of taurolidine or taurultam for the manufacture of a medicament for the prevention of metastases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010029152A Division JP2010215615A (ja) | 1997-07-31 | 2010-02-12 | 転移予防のための医薬の製造のためのタウロリジンまたはタウルルタムの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001511463A true JP2001511463A (ja) | 2001-08-14 |
| JP2001511463A5 JP2001511463A5 (enExample) | 2006-01-05 |
Family
ID=10816777
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000504921A Pending JP2001511463A (ja) | 1997-07-31 | 1998-07-31 | 転移予防のための医薬の製造のためのタウロリジンまたはタウルルタムの使用 |
| JP2010029152A Pending JP2010215615A (ja) | 1997-07-31 | 2010-02-12 | 転移予防のための医薬の製造のためのタウロリジンまたはタウルルタムの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010029152A Pending JP2010215615A (ja) | 1997-07-31 | 2010-02-12 | 転移予防のための医薬の製造のためのタウロリジンまたはタウルルタムの使用 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1001781B1 (enExample) |
| JP (2) | JP2001511463A (enExample) |
| AT (1) | ATE318141T1 (enExample) |
| DE (1) | DE69833554T2 (enExample) |
| ES (1) | ES2255172T3 (enExample) |
| GB (1) | GB9716219D0 (enExample) |
| WO (1) | WO1999006114A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000300661A (ja) * | 1999-03-29 | 2000-10-31 | Ed Geistlich Soehne Ag Fuer Chemische Industrie | 抗凝固剤／滅菌剤組成物と方法 |
| JP2005504814A (ja) * | 2001-10-01 | 2005-02-17 | ロード アイランド ホスピタル | 転移阻害のための方法 |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9626795D0 (en) | 1996-12-23 | 1997-02-12 | Geistlich Soehne Ag | Combating infection in delivery systems |
| US7132413B1 (en) | 1997-07-31 | 2006-11-07 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Anticoagulant/sterilizing compositions and methods |
| US8304390B2 (en) | 1997-07-31 | 2012-11-06 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of treatment for preventing or reducing tumor growth in the liver of patient |
| US20030027818A1 (en) * | 2001-04-03 | 2003-02-06 | Redmond H. Paul | Treatment of cancers |
| US6479481B1 (en) * | 1999-06-04 | 2002-11-12 | Ed. Geistlich Soehne Ag Fur Chemische Industrie | Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS) |
| US8030301B2 (en) | 1999-06-04 | 2011-10-04 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of cancers with methylol-containing compounds and at least one electrolyte |
| US7345039B2 (en) | 1999-06-04 | 2008-03-18 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
| US7892530B2 (en) | 1999-06-04 | 2011-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
| CN100519525C (zh) | 1999-12-06 | 2009-07-29 | 葛兰素集团有限公司 | 芳香砜类及其医疗用途 |
| ES2438535T3 (es) * | 1999-12-06 | 2014-01-17 | Geistlich Pharma Ag | Taurolidina o taurultamo para uso en el tratamiento de tumores de próstata, de colon, de pulmón y para el tratamiento del glioblastoma multiforme recurrente |
| US6641571B2 (en) | 2000-01-05 | 2003-11-04 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery |
| AU779362B2 (en) * | 2000-10-27 | 2005-01-20 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
| CA2363973C (en) * | 2000-11-28 | 2009-03-10 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
| US20030092707A1 (en) * | 2001-10-19 | 2003-05-15 | Redmond H. Paul | Treatment of breast cancer |
| CA2412012C (en) | 2001-11-20 | 2011-08-02 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage |
| CA2482687C (en) | 2003-09-29 | 2012-11-20 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of mesothelioma |
| DE07825069T1 (de) * | 2006-09-07 | 2010-04-08 | Ed Geistlich Söhne Ag Für Chemische Industrie | Verfahren zur behandlung von knochenkrebs |
| KR20210054544A (ko) * | 2018-08-31 | 2021-05-13 | 코르메딕스, 인코포레이티드 | 포유류 체내의 myc-발현 종양에 대한 타우로리딘 치료 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6117A (ja) * | 1984-06-11 | 1986-01-06 | Seikagaku Kogyo Co Ltd | ムコ多糖系癌転移抑制剤 |
| GB9015108D0 (en) * | 1990-07-09 | 1990-08-29 | Geistlich Soehne Ag | Chemical compositions |
| CA2122519C (en) * | 1994-04-29 | 2001-02-20 | Rudolf Edgar Dr. Falk | Cancer treatment and metastasis prevention |
| GB9400163D0 (en) * | 1994-01-06 | 1994-03-02 | Geistlich Soehne Ag | Membrane |
| DE19606897C2 (de) * | 1996-02-13 | 2002-08-29 | Geistlich Soehne Ag | Mittel zur Verhinderung der Tumorzellverschleppung und der Entstehung von Trokarmetastasen in der offenen und laparoskopischen Chirurgie maligner Tumoren |
-
1997
- 1997-07-31 GB GBGB9716219.2A patent/GB9716219D0/en active Pending
-
1998
- 1998-07-31 ES ES98937635T patent/ES2255172T3/es not_active Expired - Lifetime
- 1998-07-31 WO PCT/GB1998/002311 patent/WO1999006114A2/en not_active Ceased
- 1998-07-31 EP EP98937635A patent/EP1001781B1/en not_active Expired - Lifetime
- 1998-07-31 JP JP2000504921A patent/JP2001511463A/ja active Pending
- 1998-07-31 DE DE69833554T patent/DE69833554T2/de not_active Expired - Lifetime
- 1998-07-31 AT AT98937635T patent/ATE318141T1/de active
-
2010
- 2010-02-12 JP JP2010029152A patent/JP2010215615A/ja active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000300661A (ja) * | 1999-03-29 | 2000-10-31 | Ed Geistlich Soehne Ag Fuer Chemische Industrie | 抗凝固剤／滅菌剤組成物と方法 |
| JP2011152448A (ja) * | 1999-03-29 | 2011-08-11 | Ed Geistlich Soehne Ag Fuer Chemische Industrie | 抗凝固剤／滅菌剤組成物と方法 |
| JP2005504814A (ja) * | 2001-10-01 | 2005-02-17 | ロード アイランド ホスピタル | 転移阻害のための方法 |
| JP2010209101A (ja) * | 2001-10-01 | 2010-09-24 | Geistlich Pharma Ag | 転移阻害のための方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999006114A3 (en) | 1999-04-08 |
| JP2010215615A (ja) | 2010-09-30 |
| GB9716219D0 (en) | 1997-10-08 |
| DE69833554D1 (de) | 2006-04-27 |
| EP1001781A2 (en) | 2000-05-24 |
| ES2255172T3 (es) | 2006-06-16 |
| EP1001781B1 (en) | 2006-02-22 |
| ATE318141T1 (de) | 2006-03-15 |
| DE69833554T2 (de) | 2006-08-10 |
| WO1999006114A2 (en) | 1999-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010215615A (ja) | 転移予防のための医薬の製造のためのタウロリジンまたはタウルルタムの使用 | |
| Rogers et al. | Hemangiomas of the cecum: colonoscopic diagnosis and therapy | |
| Costalat et al. | Combined laparoscopic and endoscopic treatment of perforated gastroduodenal ulcer using the ligamentum teres hepatis (LTH) | |
| Gharaibeh et al. | Bupivacaine instillation into gallbladder bed after laparoscopic cholecystectomy: does it decrease shoulder pain? | |
| Mohamed et al. | Peritoneal mesothelioma | |
| US7151099B2 (en) | Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases | |
| DUNN et al. | Laparoscopic cyst marsupialization in patients with autosomal dominant polycystic kidney disease | |
| Shamim et al. | Complications of laparoscopic cholecystectomy | |
| Ceccanti et al. | Laparoscopic pyloroplasty for idiopathic non-hypertrophic pyloric stenosis in a child | |
| CN105581822A (zh) | Cit多镜联合保胆取石术 | |
| Pasternak et al. | Spinal cord disorders | |
| RU2231303C1 (ru) | Способ хирургического лечения кисты головки поджелудочной железы при хроническом осложненном панкреатите | |
| CN102552120A (zh) | 一种外科用防粘连冲洗液 | |
| DIXON et al. | Principles in the management of external fecal fistulas | |
| RU2810246C1 (ru) | Способ эндоскопического лечения кровоточащих варикозно расширенных вен пищевода и желудка | |
| CN101336929B (zh) | 腹腔内压升高用药物 | |
| Ngoc et al. | Laparoscopic anatomical hepatectomy using negative staining method with Indocyanine Green fluorescence in treatment of Hepatocellular carcinoma: a single center experiences in Viet Nam | |
| Chikwe et al. | Complications of cardiothoracic surgery | |
| CN114306375A (zh) | 聚桂醇注射液在制备治疗贲门撕裂症的药物中的应用 | |
| Edmunds et al. | Endoscopic ethanol sclerotherapy in non‐variceal gastrointestinal bleeding | |
| Baker | The repair of intestinal fistulae | |
| Lesses et al. | Toxic Effects from the Intraperitoneal Use of Sulfanilamide: Report of Two Cases | |
| RU2305497C2 (ru) | Способ лечения рака ободочной кишки | |
| Walters | II. PREOPERATIVE PREPARATION OF PATIENTS WITH OBSTRUCTIVE JAUNDICE. END-RE-SULTS IN THIRTY-FOUR CASES | |
| HARRIMAN | APPENDICITIS IN PREGNANCY· |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050620 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050620 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090518 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091013 |